Literature DB >> 29858547

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Giuseppina Stifano1, Thierry Sornasse2, Lisa M Rice1, Leo Na1, Haiyin Chen-Harris2, Dinesh Khanna3, Angelika Jahreis2, Yuqing Zhang1, Jeff Siegel2, Robert Lafyatis4.   

Abstract

OBJECTIVE: At present, there are no clinical or laboratory measures that accurately forecast the progression of skin fibrosis and organ involvement in patients with systemic sclerosis (SSc). The goal of this study was to identify skin biomarkers that could be prognostic for the progression of skin fibrosis in patients with early diffuse cutaneous SSc (dcSSc).
METHODS: We analyzed clinical data and gene expression in skin biopsy samples from 38 placebo-treated patients, part of the Roche Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (FASSCINATE) phase II study of tocilizumab in SSc. RNA samples were analyzed using nCounter. A trajectory model based on a modified Rodnan skin thickness score was used to describe 3 skin disease trajectories over time. We examined the association of skin gene expression with skin score trajectory groups, by chi-square test. Logistic regression was used to examine the prognostic power of each gene identified.
RESULTS: We found that placebo-treated patients with high expression of messenger RNA for CD14, SERPINE1, IL13RA1, CTGF, and OSMR at baseline were more likely to have progressive skin score trajectories. We also found that those genes were prognostic for the risk of skin progression and that IL13RA1, OSMR, and SERPINE1 performed the best.
CONCLUSION: Skin gene expression of biomarkers associated with macrophages (CD14, IL13RA1) and transforming growth factor β activation (SERPINE1, CTGF, OSMR) are prognostic for progressive skin disease in patients with dcSSc. These biomarkers may provide guidance in decision-making about which patients should be considered for aggressive therapies and/or for clinical trials.
© 2018, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29858547      PMCID: PMC6731768          DOI: 10.1002/art.40455

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  21 in total

Review 1.  Novel anti-fibrotic modalities for liver fibrosis: molecular targeting and regenerative medicine in fibrosis therapy.

Authors:  Yutaka Inagaki; Reiichi Higashiyama; Kiyoshi Higashi
Journal:  J Gastroenterol Hepatol       Date:  2012-03       Impact factor: 4.029

2.  Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Authors:  P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold
Journal:  Arthritis Rheum       Date:  2012-10

3.  Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.

Authors:  Lynne Shand; Mark Lunt; Svetlana Nihtyanova; Mansour Hoseini; Alan Silman; Carol M Black; Christopher P Denton
Journal:  Arthritis Rheum       Date:  2007-07

4.  Group-based trajectory modeling in clinical research.

Authors:  Daniel S Nagin; Candice L Odgers
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

5.  Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

Authors:  Paul J DeMarco; Michael H Weisman; James R Seibold; Daniel E Furst; Weng Kee Wong; Eric L Hurwitz; Maureen Mayes; Barbara White; Fredrick Wigley; Walter Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Philip J Clements
Journal:  Arthritis Rheum       Date:  2002-11

6.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2011-06

7.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.

Authors:  Michael R York; Taro Nagai; Alyson J Mangini; Raphaël Lemaire; Jean Maguire van Seventer; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2007-03

8.  Severe organ involvement in systemic sclerosis with diffuse scleroderma.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  2000-11

9.  Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis.

Authors:  Afsaneh Mozaffarian; Avery W Brewer; Esther S Trueblood; Irina G Luzina; Nevins W Todd; Sergei P Atamas; Heather A Arnett
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury.

Authors:  Sarah A Pendergrass; Everett Hayes; Giuseppina Farina; Raphael Lemaire; Harrison W Farber; Michael L Whitfield; Robert Lafyatis
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

View more
  17 in total

1.  Recent advances steer the future of systemic sclerosis toward precision medicine.

Authors:  Gemma Lepri; Michael Hughes; Cosimo Bruni; Marco Matucci Cerinic; Silvia Bellando Randone
Journal:  Clin Rheumatol       Date:  2019-11-23       Impact factor: 2.980

2.  Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Dinesh Khanna; Cathie Spino; Sindhu Johnson; Lorinda Chung; Michael L Whitfield; Christopher P Denton; Veronica Berrocal; Jennifer Franks; Bhavan Mehta; Jerry Molitor; Virginia D Steen; Robert Lafyatis; Robert W Simms; Anna Gill; Suzanne Kafaja; Tracy M Frech; Vivien Hsu; Robyn T Domsic; Janet E Pope; Jessica K Gordon; Maureen D Mayes; Elena Schiopu; Amber Young; Nora Sandorfi; Jane Park; Faye N Hant; Elana J Bernstein; Soumya Chatterjee; Flavia V Castelino; Ali Ajam; Yue Wang; Tammara Wood; Yannick Allanore; Marco Matucci-Cerinic; Oliver Distler; Ora Singer; Erica Bush; David A Fox; Daniel E Furst
Journal:  Arthritis Rheumatol       Date:  2019-12-10       Impact factor: 10.995

3.  Oncostatin M and its role in fibrosis.

Authors:  Lukasz Stawski; Maria Trojanowska
Journal:  Connect Tissue Res       Date:  2018-07-30       Impact factor: 3.417

Review 4.  Biomarkers in systemic sclerosis.

Authors:  Brian Skaug; Shervin Assassi
Journal:  Curr Opin Rheumatol       Date:  2019-11       Impact factor: 5.006

5.  Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time.

Authors:  Brian Skaug; Marka A Lyons; William R Swindell; Gloria A Salazar; Minghua Wu; Tuan M Tran; Julio Charles; Connor P Vershel; Maureen D Mayes; Shervin Assassi
Journal:  Ann Rheum Dis       Date:  2021-12-22       Impact factor: 19.103

Review 6.  Assessment of disease outcome measures in systemic sclerosis.

Authors:  Robert Lafyatis; Eleanor Valenzi
Journal:  Nat Rev Rheumatol       Date:  2022-07-20       Impact factor: 32.286

Review 7.  Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases.

Authors:  Minyang Fu; Dandan Peng; Tianxia Lan; Yuquan Wei; Xiawei Wei
Journal:  Acta Pharm Sin B       Date:  2022-01-19       Impact factor: 14.903

8.  Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.

Authors:  Brian Skaug; Dinesh Khanna; William R Swindell; Monique E Hinchcliff; Tracy M Frech; Virginia D Steen; Faye N Hant; Jessica K Gordon; Ami A Shah; Lisha Zhu; W Jim Zheng; Jeffrey L Browning; Alexander M S Barron; Minghua Wu; Sudha Visvanathan; Patrick Baum; Jennifer M Franks; Michael L Whitfield; Victoria K Shanmugam; Robyn T Domsic; Flavia V Castelino; Elana J Bernstein; Nancy Wareing; Marka A Lyons; Jun Ying; Julio Charles; Maureen D Mayes; Shervin Assassi
Journal:  Ann Rheum Dis       Date:  2019-11-25       Impact factor: 19.103

9.  Expansion of Fcγ Receptor IIIa-Positive Macrophages, Ficolin 1-Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis.

Authors:  Dan Xue; Tracy Tabib; Christina Morse; Yi Yang; Robyn T Domsic; Dinesh Khanna; Robert Lafyatis
Journal:  Arthritis Rheumatol       Date:  2022-01-18       Impact factor: 10.995

10.  Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort.

Authors:  Sara Jaafar; Alain Lescoat; Suiyuan Huang; Jessica Gordon; Monique Hinchcliff; Ami A Shah; Shervin Assassi; Robyn Domsic; Elana J Bernstein; Virginia Steen; Sabrina Elliott; Faye Hant; Flavia V Castelino; Victoria K Shanmugam; Chase Correia; John Varga; Vivek Nagaraja; David Roofeh; Tracy Frech; Dinesh Khanna
Journal:  Arthritis Res Ther       Date:  2021-06-14       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.